Remarks will highlight the latest deep learning technology from Deep Genomics for 

discovering RNA disease mechanisms and candidate therapeutics

TORONTO--(BUSINESS WIRE)--September 20, 2023 Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today that its ...

O’Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company 

Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume ...

TORONTO--(BUSINESS WIRE)--Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, today announced additions to its Board of Directors and Scientific Advisory Board which will advance its capabilities to develop oligonucleotides designed to boost protein production across ...

TORONTO AND CAMBRIDGE, MA, January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10 ...

Former Moderna CMO and COVID-19 vaccine lead brings experience building hugely successful mRNA therapeutics company to Deep Genomics. 

TORONTO AND CAMBRIDGE, MA, October 26, 2021. Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective ...

MONTREAL and TORONTO – September 20, 2021 – Mila, the Quebec Artificial Intelligence Institute, today announced the start of a partnership with Deep Genomics, a leading company in therapeutic artificial intelligence treatments. This collaboration will allow the company to join Mila's community and to take advantage ...

-       Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic 

-       Oversubscribed round led by SoftBank Vision Fund 2, with CPP Investments, Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and ...